COVID-19 vaccine reaches phase-2 trials in China
Xinhua |
Updated: 2020-06-20 21:11
Share
Share - WeChat
BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- Singer Zhou Shen: Finding myself, reaching the world
- 'Go Sage' Nie Weiping hailed and mourned
- China's Antarctic survey telescope AST3-2 completes winter observations
- China completes over 8 million hectares of land greening in 2025
- China to expand sci-tech innovation hubs into regional clusters for global influence: minister
- China cracks the code for manufacturing high-performance carbon fiber
